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Does stopping a statin 
increase the short-term risk 
of a cardiovascular event?
❚ Evidence summary
The benefits of statin therapy appear to
extend beyond the realm of their cholesterol-
lowering properties.4 These benefits, such as
reduction in post–myocardial infarction (MI)
deaths and reinfarctions, are seen quickly
after initiation of therapy. Other drugs, such
as aspirin and beta-blockers, have also been
shown to improve early outcomes when
started after cardiovascular events, although
waiting until the patient is hemodynamically
stable to initiate beta-blockade reduces the
risk of cardiogenic shock.5 If standard agents
are either not started or withdrawn after a
cardiovascular event, patients are at
increased risk of harm.6,7
When hydroxymethyl glutaryl coenzyme A
(HMG CoA) inhibitors (statins) are stopped
by asymptomatic patients, there appears to
be no increased risk of cardiovascular
events (strength of recommendation 
[SOR]: B). However, for patients who have
recently experienced a cardiovascular
event, discontinuation of statins increases
the risk of further events and death 
(SOR: B).
Rely on low-tech skills, like shared 
decision-making, to improve adherence
One might hope that all patients taking
statins would have excellent compliance,
given these drugs’ well-established benefit.
Unfortunately, long-term adherence remains
suboptimal, and patients are going to stop
their statins.1 A Canadian study2 found that
patients aged >65 years, with and without
recent acute coronary syndrome (ACS), had
low rates of adherence to statins 2 years
after initiation of therapy (40.1% for ACS,
36.1% for chronic coronary artery disease,
and 25.4% for primary prevention). A recent
Cochrane review3 found small improved
adherence despite attempted intervention
(range improvement: –3% to 25%). They
concluded no intervention aimed at improv-
ing adherence to lipid-lowing drugs can be
recommended over another, given the limit-
ed effects.
Clinicians are left to rely on low-tech
skills, such as focusing on the patient’s 
perspective and shared decision-making,
to improve  their patients’ adherence.
This focus is especially important for those
who had a recent cardiovascular event.
Nevertheless, it is reassuring that this
review did not find significantly increased
harm after abrupt stopping of statins among
stable patients without recent ACS.
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High-risk patients
who had their
statins withheld
had increased
rates of heart 
failure, arrhythmia,
shock, and death
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Physiological research. Studies of
patients with stroke and those with only
risk factors for cardiovascular disease show
that platelet activity is increased when
statins are discontinued.8,9 Additionally, tis-
sue plasminogen activator levels are
decreased after discontinuation of statins,
resulting in a relatively hypercoagulable
state.10 Animal studies of stroke in mice
showed mice whose statin was abruptly
stopped had more damage from stroke than
those whose statin was continued.11
High-risk cardiovascular patients.
Preliminary human data suggested that stop-
ping statins increased risk of recurrent events
for patients who recently had a primary car-
diovascular event. One retrospective case-
control study evaluated 4870 patients who
had statin therapy withdrawn on admission
to the hospital for non-ST segment elevation
MI (NSTEMI). Patients who had their
statins withheld had increased rates of heart
failure, arrhythmia, shock, and death (haz-
ard ratio=2.32; 95% confidence interval
[CI], 2.02–2.67).12 A post-hoc analysis of
data from the PRISM trial found that
among the 86 patients who were admitted
for chest pain and had their statin with-
drawn, a higher rate of death and nonfatal
MI was observed, compared with the 379
patients whose statins were continued (haz-
ard ratio=2.93; 95% CI, 1.64–6.27). This
effect was seen in the first week and was
independent of cholesterol levels and meas-
ures of severity of illness.13
Low-risk cardiovascular patients. A
post-hoc analysis of the washout period of
a prospective study of 9473 asymptomatic
outpatients who were previously taking
statins showed that for these lower-risk
patients, similar rates of cardiovascular
events could be expected during withdraw-
al (any statin) or initiation of atorvastatin
therapy. The monthly event rate during the
discontinuation phase was 0.20% and
during initiation was 0.26% (P=NS).14
Recommendations from others
Currently, no expert panels or specialty
bodies make recommendations regarding
how or when to discontinue statins. The
Institute for Clinical Systems Improvement
recommends that all patients with chronic
stable coronary artery disease should be
considered for statin use regardless of their
lipid levels; however, no mention of discon-
tinuing statins is made.15
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